Wedneday Beyond Meat "missed Wall Street estimates for second-quarter revenue," reports Reuters. "Consumers' growing concerns about processed foods are severely diminishing the appeal of Beyond Meat's product line, causing retailers and quick service restaurants to pull back sharply on orders," Rachel Wolff, analyst at Emarketer, said.

Retail sales of refrigerated plant-based meat alternative products in the U.S. have fallen 17.2% so far this year, and frozen plant-based meat alternatives have fallen 8.1%, according to data from SPINS... [Beyond's] revenue for the quarter ended June 28 fell nearly 20% to $75 million, compared with analysts' average estimate of $82 million, according to data compiled by LSEG.
While the company arguably invented a new market for plant-based meat substitutes, it also "owns no real intellectual property," argues The Street. "And every company in the meat and grocery business (more or less) now sells a take-off of a product that already had limited appeal..." Beyond Meat has admitted it's in trouble by hiring corporate restructuring expert John Boken from consultancy AlixPartners as interim chief transformation officer [with a focus that includes "operating expense reduction" and "broader operational efficiency"]. It has also let go of 44 employees in North America (6% of its global workforce) as it seeks to cut operating expenses amid disappointing sales... Beyond Meat also has a significant cash problem. As of June 28, 2025, Beyond Meat's cash and cash equivalents balance was $117.3 million, and total outstanding debt was $1.2 billion. The company does have time to fend off a Chapter 11 bankruptcy filing, but it also has limited, if any, prospects to meet its impending cash needs.

Scientists at the University of Maryland are developing ErythroMer, a freeze-dried artificial blood substitute made from hemoglobin encased in fat bubbles, designed to be shelf-stable for years and reconstituted with water in emergencies. With promising animal trial results and significant funding from the Department of Defense, the team aims to begin human testing within two years. NPR reports: "The No. 1 cause of preventable death on the battlefield is hemorrhage still today," says Col. Jeremy Pamplin, the project manager at the Defense Advanced Research Projects Agency. "That's a real problem for the military and for the civilian world." [Dr. Allan Doctor, a scientist at the University of Maryland working to develop the artificial blood substitute] is optimistic his team may be on the brink of solving that problem with ... ErythroMer. Doctor co-founded KaloCyte to develop the blood and serves on the board and as the firm's chief scientific officer.

"We've been able to successfully recapitulate all the functions of blood that are important for a resuscitation in a system that can be stored for years at ambient temperature and be used at the scene of an accident," he says. [...] Doctor's team has tested their artificial blood on hundreds of rabbits and so far it looks safe and effective. "It would change the way that we could take care of people who are bleeding outside of hospitals," Doctor says. "It'd be transformative." [...]

While the results so far seem like cause for optimism, Doctor says he still needs to prove to the Food and Drug Administration that his artificial blood would be safe and effective for people. But he hopes to start testing it in humans within two years. A Japanese team is already testing a similar synthetic blood in people. "I'm very hopeful," Doctor says. While promising, some experts remain cautious, noting that past attempts at artificial blood ultimately proved unsafe. "I think it's a reasonable approach," says Tim Estep, a scientist at Chart Biotech Consulting who consults with companies developing artificial blood. "But because this field has been so challenging, the proof will be in the clinical trials," he adds. "While I'm overall optimistic, placing a bet on any one technology right now is overall difficult."

San Francisco-based startup Orchid Health "screens embryos for thousands of potential future illnesses," reports the Washington Post, calling it "the first company to say it can sequence an embryo's entire genome of 3 billion base pairs." It uses as few as five cells from an embryo to test for more than 1,200 of these uncommon single-gene-derived, or monogenic, conditions. The company also applies custom-built algorithms to produce what are known as polygenic risk scores, which are designed to measure a future child's genetic propensity for developing complex ailments later in life, such as bipolar disorder, cancer, Alzheimer's disease, obesity and schizophrenia. Orchid, [founder Noor] Siddiqui said in a tweet, is ushering in "a generation that gets to be genetically blessed and avoid disease." Right now, at $2,500 per embryo-screening on top of the average $20,000 for a single cycle of IVF, Siddiqui's social network in Silicon Valley and other tech hubs is an ideal target market...

Yet several genetic scientists told The Post they doubt Orchid's core claim: that it can accurately sequence an entire human genome from just five cells collected from an early-stage embryo, enabling it to see many more single- and multiple-gene-derived disorders than other methods have. Experts have struggled to extract accurate genetic information from small embryonic samples, said Svetlana Yatsenko, a Stanford University pathology professor who specializes in clinical and research genetics. Genetic tests that use saliva or blood samples typically collect hundreds of thousands of cells. For its vastly smaller samples, Orchid uses a process called amplification, which creates copies of the DNA retrieved from the embryo. That process, Yatsenko said, can introduce major inaccuracies. "You're making many, many mistakes in the amplification," she said, rendering it problematic to declare any embryo free of a particular disease, or positive for one. "It's basically Russian roulette...."

Numerous fertility doctors and scientists also told The Post they have serious reservations about screening embryos through polygenic risk scoring, the technique that allows Orchid and other companies to predict future disease by tying clusters of hundreds or even thousands of genes to disease outcomes and in some cases to other traits, such as intelligence and height. The vast majority of diseases that afflict humans are associated with many different genes rather than a single gene... And for traits such as intelligence, polygenic scoring has almost negligible predictive capacity — just a handful of IQ points... Or parents might select against an unwanted trait, such as schizophrenia, without understanding how they may be screening out desired traits associated with the same genes, such as creativity... The American College of Medical Genetics and Genomics calls the benefits of screening embryos for polygenic risks "unproven" and warns that such tests "should not be offered" by clinicians. A pioneer of polygenic risk scores, Harvard epidemiology professor Peter Kraft, has criticized Orchid, saying on X that "the science doesn't add up" and that "waving a magic wand and changing some of these variants at birth may not do anything at all."
The article notes several startups are already providing predictions on intelligence. "In the United States, there are virtually no restrictions on the types of genetic predictions companies can offer, and no external vetting of their proprietary scoring methods."

"Eight healthy babies were born in Britain," reports Phys.org, "with the help of an experimental technique that uses DNA from three people to help mothers avoid passing devastating rare diseases to their children, researchers reported Wednesday."

Mutations in mitochondrial DNA "can cause a range of diseases in children that can lead to muscle weakness, seizures, developmental delays, major organ failure and death," and in rare cases even pre-IVF testing can't clearly detect their presence. Researchers have been developing a technique that tries to avoid the problem by using the healthy mitochondria from a donor egg. They reported in 2023 that the first babies had been born using this method... Using this method means the embryo has DNA from three people — from the mother's egg, the father's sperm and the donor's mitochondria — and it required a 2016 U.K. law change to approve it. It is also allowed in Australia but not in many other countries, including the U.S. Experts at Britain's Newcastle University and Monash University in Australia reported in the New England Journal of Medicine Wednesday that they performed the new technique in fertilized embryos from 22 patients, which resulted in eight babies that appear to be free of mitochondrial diseases. One woman is still pregnant...

Robin Lovell-Badge [a stem cell and developmental genetics scientist at the Francis Crick Institute who was not involved in the research] said the amount of DNA from the donor is insignificant, noting that any resulting child would have no traits from the woman who donated the healthy mitochondria...

In the U.K., every couple seeking a baby born through donated mitochondria must be approved by the country's fertility regulator. As of this month, 35 patients have been authorized to undergo the technique. Critics have previously raised concerns, warning that it's impossible to know the impact these sorts of novel techniques might have on future generations... But in countries where the technique is allowed, advocates say it could provide a promising alternative for some families.

"Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March," writes a Washington Post technology columnist.

"Now it's back with the same person in charge — and I still don't trust it." As of this week, genetic data from the more than 10 million remaining 23andMe customers has been formally sold to an organization called TTAM Research Institute for $305 million. That nonprofit is run by the person who co-founded and ran 23andMe, Anne Wojcicki. In a recent email to customers, the new 23andMe said it "will be operating with the same employees and privacy protocols that have protected your data." Never mind that Wojcicki and her privacy protocols are what put your DNA at risk in the first place...

The company is legally obligated to maintain and honor 23andMe's existing privacy policies, user consents and data protection measures. And as part of a settlement with states, TTAM also agreed to provide annual privacy reports to state regulators and set up a privacy board. But it hasn't agreed to take the fundamental step of asking for permission to acquire existing customers' genetic information. And it's leaving the door open to selling people's genes to the highest bidder again in the future...

Existing 23andMe customers have the right to delete their data or opt out of TTAM's research. But the new company is not asking for opt-in permission before it takes ownership of customers' DNA... Why does that matter? Because people who handed over the DNA 15 years ago, often to learn about their genetic ancestry, never imagined it might be used in this way now. Asking for new permission might significantly shrink the size (and value) of 23andMe's DNA database — but it would be the right thing to do given the rocky history. Neil M. Richards [the Washington University professor who served as privacy ombudsman for the bankruptcy court], pointed out that about a third of 23andMe customers haven't logged in for at least three years, so they may have no idea what is going on. Some 23andMe users never even clicked "agree" on a legal agreement that allowed their data to be sold like this; the word "bankruptcy" wasn't added to the company's privacy policy until 2022. And then there is an unknown number of deceased users who most certainly can't consent, but whose DNA still has an impact on their living genetic relatives...

[S]everal states have argued that their existing genetic privacy laws don't allow 23andMe to receive the information without getting permission from every single person. Virginia has an ongoing lawsuit over the issue, and the California attorney general's office told me it "will continue to fight to protect and vindicate the rights" of consumers....
Two more points of concern:

• "There is nothing in 23andMe's bankruptcy agreement or privacy statement to prevent TTAM from selling or transferring DNA to some other organization in the future."

• The article also notes a 2023 data breach affecting 6.9 million users, arguing "They haven't shown they can keep your data safe... 23andMe's financial struggles could make it hard to run a robust cybersecurity program."

Researchers have created the world's first mRNA-based vaccine against a deadly, antibiotic-resistant bacterium — and they did it using the platform developed for COVID-19 vaccines.

Medical Express publishes their announcement: The vaccine developed by the team from the Institute for Biological Research and Tel Aviv University is an mRNA-based vaccine delivered via lipid nanoparticles, similar to the COVID-19 vaccine. However, mRNA vaccines are typically effective against viruses like COVID-19 — not against bacteria like the plague... In 2023, the researchers developed a unique method for producing the bacterial protein within a human cell in a way that prompts the immune system to recognize it as a genuine bacterial protein and thus learn to defend against it.

The researchers from Tel Aviv University and the Institute for Biological Research proved, for the first time, that it is possible to develop an effective mRNA vaccine against bacteria. They chose Yersinia pestis, the bacterium that causes bubonic plague — a disease responsible for deadly pandemics throughout human history. In animal models, the researchers demonstrated that it is possible to effectively vaccinate against the disease with a single dose.
The team of researchers was led by Professor Dan Peer at Tel Aviv University, a global pioneer in mRNA drug development, who says the success of the current study now "paves the way for a whole world of mRNA-based vaccines against other deadly bacteria."

Stanford researchers have developed a blood-based AI tool that calculates the biological age of individual organs to reveal early signs of aging-related disease. The Mercury News reports: The tool, unveiled in Nature Medicine Wednesday, was developed by a research team spearheaded by Tony Wyss-Coray. Wyss-Coray, a Stanford Medicine professor who has spent almost 15 years fixated on the study of aging, said that the tool could "change our approach to health care." Scouring a single draw of blood for thousands of proteins, the tool works by first comparing the levels of these proteins with their average levels at a given age. An artificial intelligence algorithm then uses these gaps to derive a "biological age" for each organ.

To test the accuracy of these "biological ages," the researchers processed data for 45,000 people from the UK Biobank, a database that has kept detailed health information from over half a million British citizens for the last 17 years. When they analyzed the data, the researchers found a clear trend for all 11 organs they studied; biologically older organs were significantly more likely to develop aging-related diseases than younger ones. For instance, those with older hearts were at much higher risk for atrial fibrillation or heart failure, while those with older lungs were much more likely to develop chronic obstructive pulmonary disease.

But the brain's biological age, Wyss-Coray said, was "particularly important in determining or predicting how long you're going to live." "If you have a very young brain, those people live the longest," he said. "If you have a very old brain, those people are going to die the soonest out of all the organs we looked at." Indeed, for a given chronological age, those with "extremely aged brains" -- the 7% whose brains scored the highest on biological age -- were over 12 times more likely to develop Alzheimer's disease over the next decade than those with "extremely youthful brains" -- the 7% whose brains inhabited the other end of the spectrum.

Wyss-Coray's team also found several factors -- smoking, alcohol, poverty, insomnia and processed meat consumption -- were directly correlated with biologically aged organs. Poultry consumption, vigorous exercise, and oily fish consumption were among the factors correlated with biologically youthful organs. Supplements like glucosamine and estrogen replacements also seemed to have "protective effects," Wyss-Coray said. [...] The test ... would cost $200 once it could be operated at scale.

An anonymous reader quotes a report from the Associated Press: Filmmaker Peter Jackson owns one of the largest private collections of bones of an extinct New Zealand bird called the moa. His fascination with the flightless ostrich-like bird has led to an unusual partnership with a biotech company known for its grand and controversial plans to bring back lost species. On Tuesday, Colossal Biosciences announced an effort to genetically engineer living birds to resemble the extinct South Island giant moa -- which once stood 12 feet (3.6 meters) tall -- with $15 million in funding from Jackson and his partner Fran Walsh. The collaboration also includes the New Zealand-based Ngai Tahu Research Centre. "The movies are my day job, and the moa are my fun thing I do," said Jackson. "Every New Zealand schoolchild has a fascination with the moa."

The moa had roamed New Zealand for 4,000 years until they became extinct around 600 years ago, mainly because of overhunting. A large skeleton brought to England in the 19th century, now on display at the Yorkshire Museum, prompted international interest in the long-necked bird. Unlike Colossal's work with dire wolves, the moa project is in very early stages. It started with a phone call about two years ago after Jackson heard about the company's efforts to "de-extinct" -- or create genetically similar animals to -- species like the woolly mammoth and the dire wolf. Then Jackson put Colossal in touch with experts he'd met through his own moa bone-collecting. At that point, he'd amassed between 300 and 400 bones, he said.

In New Zealand, it's legal to buy and sell moa bones found on private lands, but not on public conservation areas -- nor to export them. The first stage of the moa project will be to identify well-preserved bones from which it may be possible to extract DNA, said Colossal's chief scientist Beth Shapiro. Those DNA sequences will be compared to genomes of living bird species, including the ground-dwelling tinamou and emu, "to figure out what it is that made the moa unique compared to other birds," she said. [...] The direction of the project will be shaped by Mori scholars at the University of Canterbury's Ngi Tahu Research Centre. Ngi Tahu archaeologist Kyle Davis, an expert in moa bones, said the work has "really reinvigorated the interest in examining our own traditions and mythology."

An anonymous reader quotes a report from Wired: Trey had struggled with alcoholism for 15 years, eventually drinking heavily each night before quitting in December. But staying sober was a struggle for the 36-year-old first responder from Atlanta, who did not wish to use his real name due to professional concerns. Then he discovered Alterd, an AI-powered journaling app that invites users to "explore new dimensions" geared towards psychedelics and cannabis consumers, meditators, and alcohol drinkers. In April, using the app as a tripsitter -- a term for someone who soberly watches over another while they trip on psychedelics to provide reassurance and support -- he took a huge dose of 700 micrograms of LSD. (A typicalrecreational doseis considered to be 100 micrograms.) "I went from craving compulsions to feeling true freedom and not needing or wanting alcohol," he says.

He recently asked the app's "chat with your mind" function how he had become more wise through all his AI-assisted psychedelic trips. It responded: "I trust my own guidance now, not just external rules or what others think. I'm more creative, less trapped by fear, and I actually live by my values, not just talk about them. The way I see, reflect, and act in the world is clearer and more grounded every day." "It's almost like your own self that you're communicating with," says Trey, adding he's tripped with his AI chatbot about a dozen times since April. "It's like your best friend. It's kind of crazy." The article mentions several different chatbot tools and AI systems that are being used for psychedelic therapy.

ChatGPT: "Already, many millions of people are using ChatGPT on a daily basis, and the developments may have helped democratize access to psychotherapy-style guidance, albeit in a dubious Silicon Valley style with advice that is often flush with untruths," reports Wired. The general-purpose AI chatbot is being used for emotional support, intention-setting, and even real-time guidance during psychedelic trips. While not designed for therapy, it has been used informally as a trip companion, offering customized music playlists, safety reminders, and existential reflections. Experts caution that its lack of emotional nuance and clinical oversight poses significant risks during altered states.

Alterd: Alterd is a personalized AI journal app that serves as a reflective tool by analyzing a user's entries, moods, and behavior patterns. Its "mind chat" function acts like a digital subconscious, offering supportive insights while gently confronting negative habits like substance use. Users credit it with deepening self-awareness and maintaining sobriety, particularly in the context of psychedelic-assisted growth.

Mindbloom's AI Copilot: Integrated into Mindbloom's at-home ketamine therapy program, the AI copilot helps clients set pretrip intentions, process post-trip emotions, and stay grounded between sessions. It generates custom reflections and visual art based on voice journals, aiming to enhance the therapeutic journey even outside of human-guided sessions. The company plans to evolve the tool into a real-time, intelligent assistant capable of interacting more dynamically with users.

Orb AI/Shaman Concepts (Speculative): Conceptual "orb" interfaces imagine an AI-powered, shaman-like robot facilitating various aspects of psychedelic therapy, from intake to trip navigation. While still speculative, such designs hint at a future where AI plays a central, embodied role in guiding altered states. These ideas raise provocative ethical and safety questions about replacing human presence with machines in deeply vulnerable psychological contexts.

AI in Virtual Reality and Brain Modulation Systems: Researchers are exploring how AI could coordinate immersive virtual reality environments and brain-modulating devices to enhance psychedelic therapy. These systems would respond to real-time emotional and physiological signals, using haptic suits and VR to deepen and personalize the psychedelic experience. Though still in the conceptual phase, this approach represents the fusion of biotech, immersive tech, and AI in pursuit of therapeutic transformation.

Google DeepMind's chief business officer says Alphabet's drug-discovery company Isomorphic Labs "is preparing to launch human trials of AI-designed drugs," according to a report in Fortune, "pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately." "There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer," said Colin Murdoch [DeepMind's chief business officer and president of Isomorphic Labs]. "That's happening right now."

After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. "The next big milestone is actually going out to clinical trials, starting to put these things into human beings," he said. "We're staffing up now. We're getting very close."

The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition... In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a "world-class drug design engine..."

Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. "We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful," he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. "One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease," Murdoch said. "All powered by these amazing AI tools."

"Scientists have created the first lasers made entirely from edible materials," reports Science magazine "which could someday help monitor and track the properties of foods and medications with sensors that can be harmlessly swallowed." [The researchers' report] shows that tiny droplets of everyday cooking oils can act like echo chambers of light, otherwise known as lasers. By providing the right amount of energy to an atom, the atom's electrons will excite to a higher energy level and then relax, releasing a photon of light in the process. Trap a cloud of atoms in a house of mirrors and blast them with the right amount of energy, and the light emitted by one excited atom will stimulate one of its neighbors, amplifying the atoms' collective glow...

[The researchers] shot purple light at droplets of olive oil, whose surfaces can keep photons of light bouncing around, trapping them in the process. This reflected light excited the electrons in the oil's chlorophyll molecules, causing them to emit photons that triggered the glow of other chlorophyll molecules — transforming the droplet into a laser. The energy of the chlorophyll's radiation depends on the oil droplets' size, density, and other properties. The study's authors suggest this sensitivity can be exploited to track different properties of food or pharmaceutical products.

When researchers added oil droplets to foods and then measured changes in the laser light the droplets emitted, they could reliably infer the foods' sugar concentration, acidity, exposure to high temperatures, and growth of microorganisms. They also used the lasers to encode information, with droplets of different diameters functioning like the lines of a barcode. By mixing in sunflower oil droplets of seven specific sizes — all less than 100 microns wide — the researchers encoded a date directly into peach compote: 26 April, 2017, the first international Stop Food Waste Day.
Thanks to long-time Slashdot reader sciencehabit for sharing the news.

alternative_right shares a report from ScienceAlert: The world's first commercial hybrid of silicon circuitry and human brain cells will soon be available for rent. Marketed for its vast potential in medical research, the biological machine, grown inside a British laboratory, builds on the Pong-playing prototype, DishBrain. Each CL1 computer is formed of 800,000 neurons grown across a silicon chip, and their life-support system. While it can't yet match the mind-blowing capabilities of today's most powerful computers, the system has one very significant advantage: it only consumes a fraction of the energy of comparable technologies.

AI centers now consume countries' worth of energy, whereas a rack of CL1 machines only uses 1,000 watts and is naturally capable of adapting and learning in real time. [...] When neuroscientist Brett Kagan and colleagues pitted their creation against equivalent levels of machine learning algorithms, the cell culture systems outperformed them. Users can send code directly into the synthetically supported system of neurons, which is capable of responding to electrical signals almost instantly. These signals act as bits of information that can be read and acted on by the cells. But perhaps the greatest potential for this biological and synthetic hybrid is as an experimental tool for learning more about our own brains and their abilities, from neuroscience to creativity. The first CL1 units will reportedly ship soon for $35,000 each. Remote access can apparently be rented for $300 per week.

Beeftopia shares a report from CBS News: The U.S. government is preparing to breed billions of flies and dump them out of airplanes over Mexico and southern Texas to fight a flesh-eating maggot. That sounds like the plot of a horror movie, but it is part of the government's plans for protecting the U.S. from a bug that could devastate its beef industry, decimate wildlife and even kill household pets. This weird science has worked well before.

The targeted pest is the flesh-eating larva of the New World Screwworm fly. The U.S. Department of Agriculture plans to ramp up the breeding and distribution of adult male flies -- sterilizing them with radiation before releasing them. They mate with females in the wild, and the eggs laid by the female aren't fertilized and don't hatch. There are fewer larvae, and over time, the fly population dies out. It is more effective and environmentally friendly than spraying the pest into oblivion, and it is how the U.S. and other nations north of Panama eradicated the same pest decades ago. Sterile flies from a factory in Panama kept the flies contained there for years, but the pest appeared in southern Mexico late last year. [...]

The USDA expects a new screwworm fly factory to be up and running in southern Mexico by July 2026. It plans to open a fly distribution center in southern Texas by the end of the year so that it can import and distribute flies from Panama if necessary. The New World screwworm fly is a tropical species, unable to survive Midwestern or Great Plains winters, so it was a seasonal scourge. Still, the U.S. and Mexico bred and released more than 94 billion sterile flies from 1962 through 1975 to eradicate the pest, according to the USDA. The numbers need to be large enough that females in the wild can't help but hook up with sterile males for mating. One biological trait gives fly fighters a crucial wing up: Females mate only once in their weekslong adult lives. "A similar approach to certain species of mosquito is being debated," adds Beeftopia. "The impact on ecosystems is unclear."

"Researchers are embarking on an ambitious project to construct human genetic material from scratch," reports the Guardian, "to learn more about how DNA works and pave the way for the next generation of medical therapies." Scientists on the Synthetic Human Genome (SynHG) project will spend the next five years developing the tools and knowhow to build long sections of human genetic code in the lab. These will be inserted into living cells to understand how the code operates.

Armed with the insights, scientists hope to devise radical new therapies for the treatment of diseases. Among the possibilities are living cells that are resistant to immune attack or particular viruses, which could be transplanted into patients with autoimmune diseases or with liver damage from chronic viral infections. "The information gained from synthesising human genomes may be directly useful in generating treatments for almost any disease," said Prof Jason Chin, who is leading the project at the MRC's Laboratory of Molecular Biology (LMB) in Cambridge...

For the SynHG project, researchers will start by making sections of a human chromosome and testing them in human skin cells. The project involves teams from the universities of Cambridge, Kent, Manchester, Oxford and Imperial College London... Embedded in the project is a parallel research effort into the social and ethical issues that arise from making genomes in the laboratory, led by Prof Joy Zhang at the University of Kent. "We're a little way off having anything tangible that can be used as a therapy, but this is the time to start the discussion on what we want to see and what we don't want to see," said Dr Julian Sale, a group leader at the LMB.

"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times.

"One year later, these 10 patients no longer need insulin. The other two patients need much lower doses." The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented Friday evening at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine...

Patients in the study began to need less insulin within a few months of being infused with new islet cells, and most stopped needing the hormone altogether at about six months [said Dr. Trevor Reichman, director of the pancreas and islet transplant program at University Health Network, a hospital in Toronto, and first author of the study]. He added that patients' episodes of hypoglycemia went away within the first 90 days of treatment.

If the study continues to show positive results, the company expects to submit an application to the FDA next year. "For the short term, this looks promising" for severely affected patients like those in the study," said Dr. Irl B. Hirsch, a diabetes expert at the University of Washington who was not involved in the study. But patients in the trial had to stay on drugs to prevent the immune system from destroying the new cells. Suppressing the immune system, he said, increases the risk of infections and, over the long term, can increase the risk of cancer... Patients may have to take the immunosuppressant drugs for the rest of their lives, the Vertex spokesperson said.

Longtime Slashdot reader fahrbot-bot shares a report from the Cool Down: A team of chemical engineers at the Massachusetts Institute of Technology has invented a new process to separate crude oil components, potentially bringing forward a replacement that can cut its harmful carbon pollution by 90%. The original technique, which uses heat to separate crude oil into gasoline, diesel, and heating oil, accounts for roughly 1% of all global energy consumption and 6% of dirty energy pollution from the carbon dioxide it releases.

"Instead of boiling mixtures to purify them, why not separate components based on shape and size?" said Zachary P. Smith, associate professor of chemical engineering at MIT and senior author of the study, as previously reported in Interesting Engineering. The team invented a polymer membrane that divides crude oil into its various uses like a sieve. The new process follows a similar strategy used by the water industry for desalination, which uses reverse osmosis membranes and has been around since the 1970s. [The membrane excelled in lab tests. It increased the toluene concentration by 20 times in a mixture with triisopropylbenzene. It also effectively separated real industrial oil samples containing naphtha, kerosene, and diesel.]

Space may be the perfect place to study cancer — and someday even treat it," writes Space.com: On Earth, gravity slows the development of cancer because cells normally need to be attached to a surface in order to function and grow. But in space, cancer cell clusters can expand in all directions as bubbles, like budding yeast or grapes, said Shay Soker, chief science program officer at Wake Forest's Institute for Regenerative Medicine. Since bubbles grow larger and more quickly in space, researchers can more easily test substances clinging to the edge of the larger bubbles, too. Scientists at the University of Notre Dame are taking advantage of this quirk to develop an in-space cancer test that needs just a single drop of blood. The work builds on a series of bubble-formation experiments that have already been conducted on the ISS. "If cancer screening using our bubble technology in space is democratized and made inexpensive, many more cancers can be screened, and everyone can benefit," said Tengfei Luo, a Notre Dame researcher who pioneered the technology, speaking to the ISS' magazine, Upward. "It's something we may be able to integrate into annual exams. It sounds far-fetched, but it's achievable...."

Chemotherapy patients could save precious time, too. In normal gravity, they typically have to spend a half-hour hooked up to a needle before the medicine begins to take effect, because most drugs don't dissolve easily in water. But scientists at Merck have discovered that, in space, their widely used cancer drug pembrolizumab, or Keytruda, can be administered through a simple injection, because large crystalline molecules that would normally clump together are suspended in microgravity... Someday, microgravity could even help patients recovering from surgery heal faster than they would on Earth, Soker added. "Wound healing in high pressure is faster. That's the hyperbaric treatment for wounds...."

For the Wake Forest experiment, which is scheduled to launch next spring, scientists will cut out two sections of a cancer tumor from around 20 patients. One sample will stay on Earth while the other heads to the ISS, with scientists observing the difference. The testing will be completed within a week, to avoid any interference from cosmic radiation. If successful, Soker said, it could set the stage for diagnostic cancer tests in space available to the general population — perhaps on a biomedical space station that could launch after the planned demise of the ISS. "Can we actually design a special cancer space station that will be dedicated to cancer and maybe other diseases?" Shoker asked, answering his question in the affirmative. "Pharmaceutical companies that have deep pockets would certainly support that program."

Anne Wojcicki, co-founder of 23andMe, has regained control of the bankrupt DNA-testing company after a nonprofit she controls outbid Regeneron Pharmaceuticals with a $305 million offer. The company filed for bankruptcy in March due to declining demand and fallout from a major 2023 data breach.

"The agreement with non-profit TTAM Research Institute is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals," the company said in a statement.

Since filing for bankruptcy in March, 23andMe has received data deletion requests from 1.9 million users -- around 15% of its customer base. That number was revealed by 23andMe's interim chief executive Joseph Selsavage during a House Oversight Committee hearing, during which lawmakers scrutinized the company's sale following an earlier bankruptcy auction. "The bankruptcy sparked concerns that the data of millions of Americans who used 23andMe could end up in the hands of an unscrupulous buyer, prompting customers to ask the company to delete their data," adds TechCrunch. From the report: Pharmaceutical giant Regeneron won the court-approved auction in May, offering $256 million for 23andMe and its banks of customers' DNA and genetic data. Regeneron said it would use the 23andMe data to aid the discovery of new drugs, and committed to maintain 23andMe's privacy practices. Truly deleting your personal genetic information from the DNA testing company is easier said than done. But if you were a 23andMe customer and are interested, MIT Technology Review outlines that steps you can take.

It's no longer a hypothetical question, writes the Washington Post. "In recent years, scientists have devised powerful genetic tools that may be able to eradicate mosquitoes and other pests once and for all."

But along with the ability to fight malaria, dengue, West Nile virus and other serious diseases, "the development of this technology also raises a profound ethical question: When, if ever, is it okay to intentionally drive a species out of existence...?" When so many wildlife conservationists are trying to save plants and animals from disappearing, the mosquito is one of the few creatures that people argue is actually worthy of extinction. Forget about tigers or bears; it's the tiny mosquito that is the deadliest animal on Earth. The human misery caused by malaria is undeniable. Nearly 600,000 people died of the disease in 2023, according to the World Health Organization, with the majority of cases in Africa... But recently, the Hastings Center for Bioethics, a research institute in New York, and Arizona State University brought together a group of bioethicists to discuss the potential pitfalls of intentionally trying to drive a species to extinction. In a policy paper published in the journal Science last month, the group concluded that "deliberate full extinction might occasionally be acceptable, but only extremely rarely..."

It's unclear how important malaria-carrying mosquitoes are to broader ecosystems. Little research has been done to figure out whether frogs or other animals that eat the insects would be able to find their meals elsewhere. Scientists are hotly debating whether a broader "insect apocalypse" is underway in many parts of the world, which may imperil other creatures that depend on them for food and pollination... Instead, the authors said, geneticists should be able to use gene editing, vaccines and other tools to target not the mosquito itself, but the single-celled Plasmodium parasite that is responsible for malaria. That invisible microorganism — which a mosquito transfers from its saliva to a person's blood when it bites — is the real culprit.
A nonprofit research consortium called Target Malaria has genetically modified mosquitoes in their labs (which get core funding from the Gates Foundation and from Open Philanthropy, backed by Facebook co-founder Dustin Moskovitz and his wife). ), and hopes to deploy them in the wild within five years...